Abstract Search

ba0001pp435 | Osteoporosis: treatment | ECTS2013

Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study

Roux C , McClung MR , Franchimont N , Adami S , Ebeling PR , Reid IR , Resch H , Weryha G , Daizadeh N , Wang A , Wagman RB , Eastell R

Denosumab (DMAb) has a unique profile of bone resorption inhibition: CTX decreases rapidly by 3 days and inhibition is released at the end of the 6-month dosing interval, when DMAb serum levels decrease (McClung NEJM 2006). The dynamic CTX inhibition profile is not curtailed by continued treatment. In the 3-year FREEDOM study, CTX values at 6 months were influenced by baseline CTX values and days since the 1st injection (Eastell JBMR 2011). With 3 additional ...

0 shares

ba0003oc6.4 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years

Ferrari S , Adachi JD , Lippuner K , Zapalowski C , Miller PD , Reginster J-Y , Torring O , Kendler DL , Daizadeh N , Wang A , O'Malley CD , Wagman RB , Libanati C , Lewiecki EM

Objective: Evidence for further reduction of nonvertebral fracture (NVFX) beyond 3 years of antiresorptive therapy is limited. Since long-term denosumab (DMAb) treatment is associated with continuous increases in BMD and sustained fracture reduction, we analyzed the influence of femoral neck (FN) BMD after 3 years on NVFX rates.Methods: Long-term subjects received 7 continuous years of DMAb; cross-over subjects received 3 years of placebo (FREEDOM) and 4...

0 shares

Bone Abstracts

Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study

Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years

BiosciAbstracts